UPDATE: J.P. Morgan Reiterates Overweight Rating, Raises PT on Covance
In a report published Friday, J.P. Morgan reiterated its Overweight rating on Covance (NYSE: CVD), and raised its price target from $68.00 to $70.00.
J.P. Morgan noted, “Given a diversified service offering, increasing geographical footprint, economies of scale, and growing biotechnology and pharmaceutical customer base, which have become increasingly reluctant to outsource work to smaller, less well-funded service organizations, we believe that CVD will continue to command a significant premium valuation to peers.”
Covance closed on Thursday at $67.54.
Latest Ratings for CVD
|Aug 2014||Credit Suisse||Maintains||Outperform|
|Jul 2014||JP Morgan||Maintains||Overweight|
|Jul 2014||SunTrust Robinson Humphrey||Maintains||Neutral|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.